Replies to post #648 on Outlook Therapeutics Inc (OTLK)

[maverick_1]

The INEVITABILITY of correctly reading between the lines from OTLK/FDA & Ulterior Motives of a Thermo.

The FDA informed Outlook Therapeutics that an additional adequate and well-controlled clinical trial would be required for the approval of ONS-5010 for the treatment of wet AMD. During the meetings, Outlook Therapeutics reached an agreement in principle with the FDA on a clinical trial design that would most likely allow for the resubmission of the ONS-5010 BLA as early as the end of calendar year 2024, and subsequent approval around mid-2025,

agreement in principle with the FDA on a clinical trial design that would most likely allow for the resubmission of the ONS-5010 BLA as early as the end of calendar year 2024, and subsequent approval around mid-2025, pending final agreement on a clinical trial protocol with the FDA and successful completion of the required additional clinical trial. The FDA and Outlook Therapeutics also agreed on the approaches needed to resolve the CMC comments in the CRL and Outlook Therapeutics believes these efforts should be sufficient to support approval.

SEEING The Extremes Limits of Capitalism in last TWO Decades.

The MARKETS are RIGGED: exploited by ALGO's since 2014
AND since 1980's
See DeepCapture.com

Fallacy of not acknowledging
The Peter's Principle.

Why msg bds are The Maddening Crowd

DIFFERENT STROKES for DIFFERENT FOLKS